Risperidone sustained-release - Indivior

Drug Profile

Risperidone sustained-release - Indivior

Alternative Names: Long-acting Risperidone - Indivior; RBP 7000

Latest Information Update: 27 Jan 2017

Price : $50

At a glance

  • Originator Reckitt Benckiser Pharmaceuticals
  • Developer Indivior
  • Class Antineoplastics; Antipsychotics; Isoxazoles; Piperidines; Pyrimidinones; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Schizophrenia

Most Recent Events

  • 01 Sep 2016 Reckitt Benckiser completes a phase III trial for Schizophrenia in USA (NCT02203838)
  • 01 Jul 2016 Indivior completes a phase I pharmacokinetics trial for Schizophrenia in USA (NCT02687984)
  • 30 May 2016 Phase-III development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top